Claro Advisors LLC Boosts Stock Position in Hologic, Inc. (NASDAQ:HOLX)

Claro Advisors LLC increased its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 18.4% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 3,924 shares of the medical equipment provider’s stock after acquiring an additional 609 shares during the quarter. Claro Advisors LLC’s holdings in Hologic were worth $320,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in HOLX. Wolff Wiese Magana LLC purchased a new position in shares of Hologic during the 3rd quarter worth $25,000. Innealta Capital LLC acquired a new stake in Hologic during the second quarter worth about $25,000. iA Global Asset Management Inc. purchased a new position in Hologic during the first quarter worth about $37,000. Sunbelt Securities Inc. purchased a new position in Hologic during the second quarter worth about $37,000. Finally, Cromwell Holdings LLC boosted its holdings in Hologic by 330.2% in the 3rd quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 416 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on HOLX. JPMorgan Chase & Co. lifted their price target on shares of Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Mizuho reduced their target price on Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 5th. Stephens reiterated an “overweight” rating and set a $92.00 price target on shares of Hologic in a report on Tuesday, July 30th. Evercore ISI raised their price objective on Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a research report on Tuesday, October 1st. Finally, Raymond James upped their target price on shares of Hologic from $93.00 to $95.00 and gave the company an “outperform” rating in a research report on Tuesday, November 5th. Four research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $89.91.

Hologic Stock Up 0.2 %

Shares of NASDAQ:HOLX opened at $78.79 on Tuesday. The firm has a market capitalization of $18.30 billion, a PE ratio of 23.66, a price-to-earnings-growth ratio of 2.48 and a beta of 0.98. Hologic, Inc. has a 1 year low of $67.59 and a 1 year high of $84.67. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. The firm’s 50-day moving average is $80.63 and its two-hundred day moving average is $78.28.

Hologic (NASDAQ:HOLX) last announced its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, hitting the consensus estimate of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The firm had revenue of $987.90 million for the quarter, compared to the consensus estimate of $978.25 million. During the same period in the prior year, the firm earned $0.89 EPS. The firm’s revenue for the quarter was up 4.5% on a year-over-year basis. Analysts predict that Hologic, Inc. will post 4.27 EPS for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.